REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 AM Eastern Time.
A live audio webcast and replay of the presentation will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
A new study predicts that Bitcoin could hit $1 million as early as 2027 as…
In a notable shift in market dynamics, the latest data from the Commodity Futures Trading…
In a notable development for the agricultural commodities market, the U.S. Commodity Futures Trading Commission…
In the latest market activity, speculative positions in the New Zealand Dollar (NZD) have shown…
In a recent update from the Commodity Futures Trading Commission (CFTC), the Japanese Yen (JPY)…
The Brazilian Real (BRL) experienced an optimistic shift in market sentiment as reported by the…
This website uses cookies.